Biocytogen's RenMab, RenLite, and RenNano humanized mice are powerful platforms for fully human therapeutic antibody discovery. The RenMab model, our best-in-class humanized antibody mouse, is ideal for the discovery of fully human therapeutic antibodies.
The RenLite mouse model is specially designed for bispecific and multispecific antibody discovery, as the common light chain eliminates chain mispairing issues during bispecific antibody development. These models have also been further modified to support the discovery of TCR-mimic antibodies and anti-GPCR antibodies.
The RenMab™ mouse model completely replaced murine variable regions with full human heavy and kappa light chain V(D)J loci in situ. This results in a higher potential for antibody drug development, as the RenMab™ Mouse has a normal immune system comparable to that of wild-type mice and greater diversity of antibody genes.
Researchers can use this platform to generate highly specific, diverse, and high-affinity antibody-based drugs.
Learn MoreThe RenLite® mouse model replaces murine heavy chain variable regions with human ones while replacing only one κ light chain VJ locus with its human counterpart. The resulting antibodies have diverse epitopes and high affinities like those produced by wild-type mice but also allow for more efficient downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs).
Learn MoreThe RenNano® mouse contains complete human heavy chain variable genes along with modified mouse constant regions. It generates heavy-chain-only antibodies (HCAbs) that exhibit great diversity and nM-level binding affinity independent of light chains. These HCAbs are ideal building blocks for bispecific/multispecific antibodies and CAR cell therapies since they can be used to derive single-domain antibodies (sdAbs), or VHHs.
Learn MoreThe RenTCR-mimic™ mouse has been further modified to express human leukocyte antigen (HLA) genes. Through high-throughput screening, antibodies with high specificity and affinity against intracellular tumor antigens can be obtained, facilitating the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
Learn More
To address the growing demand for fully human antibody drugs, Biocytogen has developed an advanced fully human antibody platform, RenMice, with cutting-edge technology. The proprietary RenMice™ platform consists of RenMab™ mice, common light chain RenLite® mice and RenNano® mice, which enables new drug development with diverse modalities, including fully human monoclonal antibody drugs, bispecific/multispecific antibody drugs, and VHH drugs.
We offer a diverse portfolio of clinical and preclinical assets to meet the drug development needs of various partners. Our competitive end-to-end drug development capabilities, powered by RenMice, enable us to consistently deliver innovative molecules.
